# BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

> **NCT00602472** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1058 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** linagliptin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00602472
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 1058 (ACTUAL)
- **Last updated:** 2014-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602472, "BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00602472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*